Acute Diverticulitis and C-Reactive Protein as a Prognostic Marker

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified April 2013 by Corporacion Parc Tauli
Sponsor:
Information provided by (Responsible Party):
LAURA MORA LOPEZ, Corporacion Parc Tauli
ClinicalTrials.gov Identifier:
NCT01825967
First received: March 29, 2013
Last updated: April 9, 2013
Last verified: April 2013
  Purpose

The management of acute diverticulitis maybe better if we have prognostic markers of evolution.

Hypothesis: C-reactive protein maybe a good prognostic marker of evolution of acute diverticulitis.

The investigators need to know the values of C-reactive protein to predict evolution of acute diverticulitis.


Condition Intervention
Acute Diverticulitis
Other: C-reactive protein

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration: 30 Days
Official Title: Predictive Value of C-Reactive Protein in Acute Diverticulitis

Resource links provided by NLM:


Further study details as provided by Corporacion Parc Tauli:

Primary Outcome Measures:
  • C-Reactive Protein [ Time Frame: 24 Hours ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 30
Study Start Date: April 2013
Estimated Study Completion Date: April 2014
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Acute Diverticulitis
We measured C-reactive protein in all the patients diagnosed with acute diverticulitis
Other: C-reactive protein
measured C-reactive protein in all patients with acute diverticulitis

Detailed Description:

A prospective observational study. All the patients with TC-diagnosis of acute diverticulitis (AD) had a C-reactive protein (PCR) in the initial blood test.

The investigators will predict evolution of AD with the PCR initial.

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

All Patients with Acute Diverticulitis

Criteria

Inclusion Criteria:

  • Acute Diverticulitis

Exclusion Criteria:

  • Other Abdominal Pathologies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01825967

Contacts
Contact: MORA L. LAURA, MD 34639101033 Lmora@tauli.cat

Locations
Spain
Corporacion Parc Tauli Not yet recruiting
Sabadell, Barcelona, Spain, 08208
Contact    34937231010 ext 21490    Lmora@tauli.cat   
Contact: Laura Mora    3493723101033 ext 21490    Lmora@tauli.cat   
Corporacion parc tauli Not yet recruiting
Sabadell, Sabadell-Barcelona, Spain, 08208
Contact: MORA L. LAURA, MD    34639101033    Lmora@tauli.cat   
Principal Investigator: MORA L. LAURA, MD         
Corporacion Parc Tauli Not yet recruiting
Sabadell, Sabadell/barcelona, Spain, 08208
Contact: MORA L. LAURA, MD    34639101033    Lmora@tauli.cat   
Corporacion Parc Tauli
Sabadell, Sabadell/barcelona, Spain, 08208
Sponsors and Collaborators
Corporacion Parc Tauli
Investigators
Principal Investigator: MORA LAURA, MD Corporacion Parc Tauli
  More Information

No publications provided

Responsible Party: LAURA MORA LOPEZ, General Surgeon, Corporacion Parc Tauli
ClinicalTrials.gov Identifier: NCT01825967     History of Changes
Other Study ID Numbers: 2013/532
Study First Received: March 29, 2013
Last Updated: April 9, 2013
Health Authority: Spain: Ethics Committee

Additional relevant MeSH terms:
Diverticulitis
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on July 22, 2014